The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | ELM-2 trial: using ctDNA and MRD to measure odronextamab outcomes in DLBCL and FL
Jon Arnason, MD, Beth Israel Deaconess Medical Center, Boston, MA, discusses the ELM-2 study (NCT03888105), focussing on the utilization of circulating tumor DNA (ctDNA) and measurable residual disease (MRD) to assess responses to odronextamab for patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trial found that MRD negativity correlated with improved progression-free survival (PFS), and TP53 mutations were associated with worse PFS, although this was not statistically significant. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Bristol Myers Squibb
